Dogwood Therapeutics, Inc. (DWTX)
| Market Cap | 69.34M +640.5% |
| Revenue (ttm) | n/a |
| Net Income | -36.04M |
| EPS | -1.71 |
| Shares Out | 33.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 85,886 |
| Open | 2.290 |
| Previous Close | 2.290 |
| Day's Range | 2.040 - 2.344 |
| 52-Week Range | 1.280 - 9.500 |
| Beta | 1.83 |
| Analysts | Buy |
| Price Target | 14.00 (+586.28%) |
| Earnings Date | Aug 13, 2026 |
About DWTX
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for DWTX stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 586.28% from the latest price.
News
Dogwood Therapeutics Transcript: KOL event
Halneuron, a selective NaV1.7 inhibitor, targets a large unmet need in chemotherapy-induced neuropathic pain, showing durable efficacy and strong tolerability in clinical trials. Synthetic TTX manufacturing ensures supply and IP protection, with phase III and NDA milestones planned.
Dogwood Therapeutics Slides: KOL event
Dogwood Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines...
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –
Dogwood Therapeutics Earnings release: Q2 2026
Dogwood Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Dogwood Therapeutics Quarterly report: Q2 2026
Dogwood Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Dogwood Therapeutics Slides: Corporate presentation
Dogwood Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Dogwood enrolls first 200 patients in HAL-CINP trial
Dogwood (DWTX) announced it has enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in…
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, t...
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and ...
Dogwood Therapeutics Slides: Corporate presentation
Dogwood Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 30, 2026.
Dogwood begins Phase 2b extension study for Halneuron
Dogwood (DWTX) Therapeutics announced commencement of a new Halneuron chemotherapy induced neuropathic pain phase 2b extension study. “Neuropathic pain is a difficult to treat chronic condition, as ev...
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
Dogwood Therapeutics Earnings release: Q1 2026
Dogwood Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Dogwood Therapeutics Quarterly report: Q1 2026
Dogwood Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -
Dogwood Therapeutics Slides: Corporate presentation
Dogwood Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today...
Dogwood Therapeutics Proxy statement: Proxy filing
Dogwood Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood announces commercialization partnership with PRIDCor
Dogwood (DWTX) announced a global development and commercialization partnership with PRIDCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-assoc...
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royal...
Dogwood Therapeutics Proxy statement: Proxy filing
Dogwood Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood announces FDA acceptance of SP16 investigational new drug application
Dogwood (DWTX) announced FDA acceptance of an investigational new drug application for its development candidate SP16, administered intravenously, for the treatment of chemotherapy-induced pain and pe...
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...
Dogwood Therapeutics Annual report: Q4 2025
Dogwood Therapeutics has published its Q4 2025 annual report on March 18, 2026.